Skip to main content

Multiple Myeloma

First-Line Use of Daratumumab, Lenalidomide, and Dexamethasone Confers Survival Benefit Compared with Second-Line Use of Daratumumab-Based Regimens in Transplant-Ineligible Patients with Multiple Myeloma

End-of-Study Analysis of the LYRA Study of Daratumumab Maintenance Therapy Following DARA plus CyBorD Induction Therapy in MM

MagnetisMM-1 Trial Results of Elranatamab in Patients with RRMM

Isatuximab Short-Duration, Fixed-Volume Infusion plus VRd for Patients with NDMM Ineligible or with No Intent for Immediate ASCT

Daratumumab plus Ixazomib, Lenalidomide, and Dexamethasone as Extended Induction and Consolidation Followed by Lenalidomide Maintenance in Standard-Risk Transplant-Eligible NDMM

Results of the Phase 2 HOVON 143 Study of Induction Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Intermediate-Fit Patients with NDMM

Management of Belantamab Mafodotin–Associated Corneal Events in Patients with RRMM

18-Month Analysis of the Phase 3 ANDROMEDA Study of Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain Amyloidosis

Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a BCMA x CD3 Bispecific Antibody, in RRMM

Updated Results of the KarMMa Trial of Idecabtagene Vicleucel CAR T-Cell Therapy in Patients with RRMM

1
2
3
4
5
6
7

Page 4 of 11
Results 31 - 40 of 104